JDRF Presents Dr. Colin Dayan with the 2023 JDRF Rumbough Award

Award recognizes outstanding efforts in type 1 diabetes research  

New York, April 18, 2024—JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces Colin Dayan, M.D., Ph.D., as the recipient of the 2023 JDRF Rumbough Award in recognition of his remarkable accomplishments in T1D research.

The JDRF David Rumbough Award acknowledges an individual who has made outstanding contributions in the field of T1D that have significantly accelerated the JDRF mission.

For over 20 years, Dr. Dayan has been a leader in T1D immunotherapy research, and his work has been central to JDRF’s research strategy and overall mission. He is leading efforts to bring teplizumab, the first disease-modifying therapy approved by the U.S. Food and Drug Administration that can delay clinical T1D in individuals in early stages, to Europe and the UK to expand treatment options available in these areas. He is a leading member of the JDRF-funded UK T1D Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve T1D clinical trial delivery. Currently, Professor Dayan serves as chair of Clinical Diabetes and Metabolism and head of section at Cardiff University School of Medicine and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford.

“Dr. Dayan has played a significant role in advancing disease-modifying therapies for type 1 diabetes that will continue to have a profound impact on the global T1D research community and those who are affected by the condition,” said JDRF Chief Scientific Officer Sanjoy Dutta, Ph.D. “JDRF is proud to honor Dr. Dayan for his indelible contributions and work that support and further our mission.”

JDRF Research award recipients were recognized at a ceremony in New York City earlier in April 2024.


About JDRF

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes (T1D)

T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.


Media Contact:

Casey Fielder